Portefeuille d'ETF XBI (NYSE) - Page 6 | MetaTrader

Afficher le graphique complet Full chart

Aperçu Toutes les participations Heatmap

Principaux titres en portefeuille Market Value Shares Weight %

D

DAWN Day One Biopharmaceuticals Inc 24.2 M 2.6 M 0.3%

ORIC ORIC Pharmaceuticals Inc 24.0 M 2.9 M 0.3%

REPL Replimune Group Inc 22.7 M 2.3 M 0.3%

SPRY ARS Pharmaceuticals Inc 22.3 M 1.9 M 0.3%

IBRX ImmunityBio Inc 19.9 M 10.1 M 0.3%

ORKA Oruka Therapeutics Inc 19.3 M 637.7 K 0.2%

CTMX CytomX Therapeutics Inc 19.3 M 4.5 M 0.2%

OLMA Olema Pharmaceuticals Inc 18.6 M 745.8 K 0.2%

RAPT Therapeutics Inc 18.5 M 546.6 K 0.2%

SANA Sana Biotechnology Inc 18.5 M 4.5 M 0.2%

EBS Emergent BioSolutions Inc 18.2 M 1.5 M 0.2%

GERN Geron Corp 18.0 M 13.6 M 0.2%

KALV KalVista Pharmaceuticals Inc 17.6 M 1.1 M 0.2%

GLUE Monte Rosa Therapeutics Inc 17.5 M 1.1 M 0.2%

UPB Upstream Bio Inc 17.4 M 641.1 K 0.2%

SION Sionna Therapeutics Inc 16.8 M 409.1 K 0.2%

LXEO Lexeo Therapeutics Inc 16.8 M 1.7 M 0.2%

BCAX Bicara Therapeutics Inc 16.7 M 991.2 K 0.2%

VSTM Verastem Inc 16.5 M 2.1 M 0.2%

GOSS Gossamer Bio Inc 16.1 M 5.2 M 0.2%

1
2
3
4
5
6
7
8

Nouvelles

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Jefferies abaisse la note de Tango Therapeutics en raison de la valorisation

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

La vente à découvert d’Intellia progresse le plus parmi les biotechs

What's The Dominant Trend In Earnings: AI Or Geopolitics?